IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Cytokines in psoriasis

(2015) Jaymie Baliwag et al.   CYTOKINE

Clinical improvement in psoriasis with specific targeting of interleukin-23

(2015) Tamara Kopp et al.   NATURE

IκBζ is a key driver in the development of psoriasis

(2015) Claus Johansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci

(2015) Lam C. Tsoi et al.   Nature Communications

Immunology of Psoriasis

(2014) Michelle A. Lowes et al.   Annual Review of Immunology

Cellular sources of IL-17 in psoriasis: a paradigm shift?

(2014) Romy R. M. C. Keijsers et al.   EXPERIMENTAL DERMATOLOGY

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

(2014) Howard Sofen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Transcriptome Analysis of Psoriasis in a Large Case–Control Sample: RNA-Seq Provides Insights into Disease Mechanisms

(2014) Bingshan Li et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis

(2014) Ellen Witte et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin 17A: Toward a new understanding of psoriasis pathogenesis

(2014) Charles W. Lynde et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model

(2014) Andrea Chiricozzi et al.   PLoS One

I B-  controls the constitutive NF- B target gene network and survival of ABC DLBCL

(2013) H. Nogai et al.   BLOOD

Enhanced Apoptosis by Disruption of the STAT3-IκB-ζ Signaling Pathway in Epithelial Cells Induces Sjögren’s Syndrome-like Autoimmune Disease

(2013) Atsushi Okuma et al.   IMMUNITY

Jun Activation Domain-binding Protein 1 (JAB1) Is Required for the Optimal Response to Interferons

(2013) Ryuta Muromoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

IL-17A and IFN-γ Synergistically Induce RNase 7 Expression via STAT3 in Primary Keratinocytes

(2013) Maren Simanski et al.   PLoS One

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis

(2012) Mayte Suárez-Fariñas et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis

(2011) Yijun Carrier et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin-17 and its expanding biological functions

(2010) Sheng Xu et al.   Cellular & Molecular Immunology

Induction of Neutrophil Gelatinase-associated Lipocalin Expression by Co-stimulation with Interleukin-17 and Tumor Necrosis Factor-α Is Controlled by IκB-ζ but neither by C/EBP-β nor C/EBP-δ

(2010) Joachim R. Karlsen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IκBζ regulates TH17 development by cooperating with ROR nuclear receptors

(2010) Kazuo Okamoto et al.   NATURE

Biology of interleukin-22

(2010) Kerstin Wolk et al.   Seminars in Immunopathology

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

(2009) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin

(2009) Patrick A. M. Jansen et al.   PLoS One

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways

(2008) K.E. Nograles et al.   BRITISH JOURNAL OF DERMATOLOGY

Chemokines and other mediators as therapeutic targets in psoriasis vulgaris

(2008) Bernhard Homey et al.   CLINICS IN DERMATOLOGY

Requirements for Two Proximal NF-κB Binding Sites and IκB-ζ in IL-17A-induced Human β-Defensin 2 Expression by Conducting Airway Epithelium

(2008) Cheng-Yuan Kao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY